The complex medical-surgical treatment in septical states

Clinica 2 Chirurgie „Constantin Ţîbîrnă”, Catedra 2 Chirurgie USMF „N.Testemiţanu”, Chişinău, Republica Moldova, Al XI-lea Congres al Asociației Chirurgilor „Nicolae Anestiadi” din Republica Moldova și cea de-a XXXIII-a Reuniune a Chirurgilor din Moldova „Iacomi-Răzeșu” 27-30 septembrie 2011Introducere: Conform concepţiilor moderne, sepsisul reprezintă o reacţie sistemică către agresia microbiană cu expulzia incontrolabilă a mediatorilor inflamaţiei şi dereglări grave de microcirculaţie, asociate hipoxiei tisulare. Astfel este argumentată utilizarea metodelor noi de inactivare a metaboliţilor proinflamatorii şi sistarea stresului oxidativ cu corijarea hipoxiei hemocirculatorii sistemice. Scopul studiului a constituit estimarea posibilităţilor aplicării ozonoterapiei sistemice în tratamentul complex medico-chirurgical la bolnavii cu stări septice. Material şi metode: Studiul dat include analiza retrospectivă a rezultatelor tratamentului la 382 bolnavi cu sepsis chirurgical (bărbaţi-199, femei-183, vîrsta medie-47+/-3,1 ani), trataţi în Clinicele Chirurgie şi ATI ale SCM “Sfînta Treime” în perioada aa.2005-2010. Diagnosticul de sepsis a fost stabilit conform criteriilor Bone R. Obligatoriu s-a recurs la examenul bacteriologic cu aprecierea antibioticogramei, în baza căreea s-a elaborat o schemă optimă de conduită în tratamentul antimicrobian.. Ozonoterapia sistemică s-a efectuat la 84 pacienţi prin perfuzii de Sol NaCl 0,9%-400,0 ml saturată cu ozon, cu o concentraţie a O3 în limite de 800-1200 mkg/l în amestecul ozonat-oxigenat. Rezultate: Hemocultura pozitivă a fost stabilită în 132 (34,5%) cazuri. Monoinfecţia - în 36. cazuri, inclusiv bacili Gram negativi-28 (77%); Gram pozitivi -8 (23%). La 96 bolnavi a fost identificată poliinfecţie. Durata medie de spitalizare a constituit 21+/-1,7 zile. Însănătoşirea a survenit în 317 (83%) cazuri. Au decedat 65 pacienţi, ce atestă o letalitate de 17.%. În lotul pacienţilor la care s-a aplicat ozonoterapia sistemică letalitatea a constituit 12 pacienţi (14,2%). Concluzii: Rezultatele obţinute demonstrează persistenţa dominaţiei sepsisului Gram negativ. Ozonoterapia sistemică în stările septice micşorează mortalitatea spitalicească.Introduction: According to modern concepts, sepsis is a systemic response to microbial aggression with uncontrollable expulsion of mediators of inflammation and disorders of microcirculation serious, associated with tissue hypoxia. So appear to be motivated the using of new methods for inactivation of proinflammatory metabolites and oxidative stress with correction and stopping of systemic hemocirculating hypoxia. Aim: The purpose of the study was estimation of possibility of systemic ozone therapy in the complex medical and surgical treatment in patients with sepsis. Material and methods: This study includes retrospective analysis of treatment results from 382 patients with surgical sepsis (men-199, female 183, average age, 47 + / -3.1 years) treated in the clinics of surgery and ATI SCM “Sfînta Treime”from aa.2005-2010. The diagnosis of sepsis was established according to criteria R. Bone with obligatory using of antibioticogramme. Bazed on bacterial appreciation, was have performed the scheme to prepare optimal conduct for antimicrobial treatment. Ozone therapy was performed in 84 patients by systematiically infusion of Sol. NaCl 0.9% -400.0 ml, saturated with ozone at a concentration of O3 in the range of 800-1200 mkg / l ozone-oxygen in the mixture. Results: Positive blood culture was established in 132 (34.5%) cases. Monoinfection was stabilited in 36. cases, including Gram-negative bacilli- 28 (77%), Gram positive -8 (23%). 96 patients were identified poliinfection. Average length of stay was 21 + / -1.7 days. Recovery occurred in 317 (83%) cases. Diedet 65 patients (17%). In the group of patients who received systemic Ozone therapy lethality was 12 patients (14.2%). Conclusions: The results demonstrate the domination of Gram-negative sepsis. The application of systemic Ozone therapy decreased hospital mortality in septic states

Ultrahigh energy neutrinos at the pierre auger observatory

The observation of ultrahigh energy neutrinos (UHEs) has become a priority in experimental astroparticle physics. UHEs can be detected with a variety of techniques. In particular, neutrinos can interact in the atmosphere (downward-going ) or in the Earth crust (Earth-skimming ), producing air showers that can be observed with arrays of detectors at the ground. With the surface detector array of the Pierre Auger Observatory we can detect these types of cascades. The distinguishing signature for neutrino events is the presence of very inclined showers produced close to the ground (i.e., after having traversed a large amount of atmosphere). In this work we review the procedure and criteria established to search for UHEs in the data collected with the ground array of the Pierre Auger Observatory.This includes Earth-skimming as well as downward-going neutrinos. No neutrino candidates have been found, which allows us to place competitive limits to the diffuse flux of UHEs in the EeV range and above

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody response against the S1 receptor binding domain (S1-RBD) of the SARS-CoV-2 spike protein and live SARS-CoV-2 neutralisation compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases. Method: We did a multicentre, open-label, parallel-group, randomised, superiority trial in secondary-care rheumatology and dermatology clinics in 26 hospitals in the UK. Adults (aged ≥18 years) with immune-mediated inflammatory diseases taking methotrexate (≤25 mg per week) for at least 3 months, who had received two primary vaccine doses from the UK COVID-19 vaccination programme were eligible. Participants were randomly assigned (1:1) using a centralised validated computer program, to temporarily suspend methotrexate treatment for 2 weeks immediately after COVID-19 booster vaccination or continue treatment as usual. The primary outcome was S1-RBD antibody titres 4 weeks after COVID-19 booster vaccination and was assessed masked to group assignment. All randomly assigned patients were included in primary and safety analyses. This trial is registered with ISRCTN, ISRCTN11442263; following a pre-planned interim analysis, recruitment was stopped early. Finding: Between Sept 30, 2021, and March 7, 2022, we screened 685 individuals, of whom 383 were randomly assigned: to either suspend methotrexate (n=191; mean age 58·8 years [SD 12·5], 118 [62%] women and 73 [38%] men) or to continue methotrexate (n=192; mean age 59·3 years [11·9], 117 [61%] women and 75 [39%] men). At 4 weeks, the geometric mean S1-RBD antibody titre was 25 413 U/mL (95% CI 22 227–29 056) in the suspend methotrexate group and 12 326 U/mL (10 538–14 418) in the continue methotrexate group with a geometric mean ratio (GMR) of 2·08 (95% CI 1·59–2·70; p<0·0001). No intervention-related serious adverse events occurred. Interpretation: 2-week interruption of methotrexate treatment in people with immune-mediated inflammatory diseases enhanced antibody responses after COVID-19 booster vaccination that were sustained at 12 weeks and 26 weeks. There was a temporary increase in inflammatory disease flares, mostly self-managed. The choice to suspend methotrexate should be individualised based on disease status and vulnerability to severe outcomes from COVID-19. Funding: National Institute for Health and Care Research